Abbott's $21B takeover ends Exact Sciences' Nasdaq era forever
Exact Sciences has officially left the Nasdaq stock exchange after a major acquisition. The company's shares stopped trading on March 23, 2026, following a $21 billion takeover by healthcare giant Abbott Laboratories. Shareholders received $105 in cash for each share they held. The deal was finalised on March 23, 2026, with Abbott fully absorbing Exact Sciences as a subsidiary. All directors and senior executives of the company resigned immediately after the merger closed. Their departure marked the end of Exact Sciences as an independent business.
Trading of Exact Sciences shares on Nasdaq ended on March 20, with a formal suspension taking effect three days later. Convertible debt tied to the company will now be exchanged for cash payments instead of equity. Before the acquisition, Abbott's market value stood at around $189.49 billion, though updated figures after the deal have not yet been released.
The total transaction was valued at approximately $21 billion, making it one of Abbott's largest purchases in recent years. Exact Sciences no longer exists as a publicly traded company. Its operations now fall under Abbott's control, and former shareholders have been compensated. The merger reshapes Abbott's portfolio, adding Exact Sciences' diagnostic and cancer-detection technologies to its offerings.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
